Pharma News

Innovative biologicals development must be preserved

Home/Pharma News | Posted 26/01/2010

As reported by Gene Quinn on IPWatchdog.com, for many months we have been hearing about the US government attempts to “reform” health care in the United States, and in the first weekend of December 2009 the US Senate was actually working, as the contentious debate continues. Even a relatively rare Presidential visit to Capitol Hill was scheduled for the afternoon of 6 December 2009, presumably so President Obama can rally the troops for whatever lies ahead. While patent policy has not taken centre stage in these debates, it is hard to ignore the under current that rages through the debates. Health care costs too much, so costs need to be contained. Of course, market initiatives like a national heath insurance market, which would lower premiums for everyone overnight, are not being considered.

Pfizer plans to launch biosimilars of Top 10–15 biologicals

Home/Pharma News | Posted 22/01/2010

Pfizer, which became the biggest drugmaker selling widely prescribed pills such as the Lipitor heart medicine, is preparing to enter the business of making cheaper copies of pricey, injectable drugs from biotechnology.

Establishing an API manufacturing base in China

Home/Pharma News | Posted 21/01/2010

According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.

China API sourcing: the way forward

Home/Pharma News | Posted 21/01/2010

According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.

Can China retain its API sourcing appeal?

Home/Pharma News | Posted 21/01/2010

China has a burgeoning active pharmaceutical ingredient (API) manufacturing base, albeit one focused largely on achieving quick profits in the domestic sector. According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.

China's appeal of the Chinese API sourcing market

Home/Pharma News | Posted 21/01/2010

According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.

Sourcing APIs from China

Home/Pharma News | Posted 21/01/2010

According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.

China is not the low-cost option in every category

Home/Pharma News | Posted 21/01/2010

According to an analysis by Robert Kennedy, Manager of Industry Research for Thomson Reuters API Intelligence, as published in Scrip News of 9 December 2009, a striking number of Chinese companies are gearing up to supply pharmaceutical ingredients to the regulated markets of the west.

Considerations about the exclusivity period of biologicals

Home/Pharma News | Posted 19/01/2010

A proposal by US Democratic Representative Anna Eshoo included in the US House health reform bill, would give developers of innovative biomedical drugs 12 years of data exclusivity from generic competition, significantly extending their patent rights, writes Los Angeles Times columnist Michael Hiltzik.

Emerging markets: a clearer categorisation needed

Home/Pharma News | Posted 08/01/2010

Emerging markets are a popular topic at the moment, with pharma firms seeking sales growth outside the mature and slowing markets of the west.